MedTrace Logo

Cardiac Safety of Lansoprazole and Domperidon Combination

NCT03355170 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-01-05

No results posted yet for this study

Summary

The aim of current study is to compare safety and efficacy of lansoprazole/domperidone 30/30 mg sustained release capsules (brand name: Duolans) and lansoprazole 30 mg micropellet capsules (brand name: Lasotab) in GERD patients in terms of cardiac safety.

Conditions

  • GERD
  • Cardiac Event
  • Safety Issues

Interventions

COMBINATION_PRODUCT

Lansoprazole/Domperidone

Experimental

DRUG

Lansoprazole

Active comparator

Sponsors & Collaborators

  • Neutec Ar-Ge San ve Tic A.Ş

    lead INDUSTRY

Principal Investigators

  • Serhat Bor, Prof Dr · Ege University Medical Faculty Gastroenterology Dep.

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2018-12-01
Completion
2019-01-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03355170 on ClinicalTrials.gov